Amylin Pharmaceuticals, Inc.Uniquely Positioned to Build a Franchise in Metabolic Diseases

• Two late-stage, first-in-class diabetes drug candidates

  • SYMLIN™ (pramlintide acetate)
    • Type 1 and insulin-using type 2 diabetes
    • NDA amendment planned for submission in 1H 2003
  • AC2993 (exenatide)
    • Type 2 diabetes
    • Global collaboration with Lilly
    • Phase 3 AMIGO trials enrolled
    • NDA submission planned for 2004

• Building on our strengths

  • Cardiovascular
  • Obesity

Improving the Lives of People with Metabolic Diseases

Previous slide

Next slide

Back to first slide

View graphic version